Tetra Bio-Pharma Discusses the Potential of Their ARDS-003 Drug in the Fight Against COVID-19 with the Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - June 22, 2020) - The Stock Day Podcast welcomed Tetra Bio-Pharma (TSXV: TBP) (OTCQB: TBPMF) ("the Company"), a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed and approved, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Chief Regulatory Officer and CEO of the Company, Dr. Guy Chamberland, joined Stock Day host Everett Jolly.

Jolly began the interview by asking about the Company's non-clinical safety program, which has been developed to initiate studies in both healthy volunteers and patients. "In the case of COVID-19, we have to be a responsible company," said Dr. Chamberland. "We need the ability, from the regulatory point of view, to be able to be able to get into the patient as soon as we can to try and help give options to physicians," he continued. "If the second wave of COVID-19 hits very hard, we have to be ready."

"You believe that you can help COVID-19 patients, is that correct?", asked Jolly. "This is correct," said Dr. Chamberland. "Panag Pharma, the company we acquired more than a year ago, for over ten years has specifically been developing this ARDS-003 drug for treating the cytokine storm that results in sepsis," continued Dr. Chamberland. "We've shown that we can reduce the cells that cause the inflammatory response and also reduce the cytokine themselves, so it's a dual response," he added.

The conversation then turned to the Company's decision to prioritize the Reborn© trials over the Serenity© trials. "We were facing the challenges of running a trial, called Serenity©, during COVID-19," explained Dr. Chamberland, noting that this type of trial requires several hospital visits and is more costly. He then shared that the Company looked to the development of their cannabinoid-derived Breakthrough Pain trial, Reborn©, which could show that CAUMZ has the potential to replace opioid solutions. "We decided to prioritize Reborn© from a business and financial point of view," said Dr. Chamberland, noting that the Reborn© trial also requires less patients.

"The FDA is fast-tracking a lot of decisions right now," said Dr. Chamberland, adding that the Company's COVID-19 drug is currently under a review just after a week of being submitted. "There's huge time savings that we're seeing right now from regulators. They're doing a great job."

"What happens to your drug for the Cytokine Release Syndrome (CRS) storm if a vaccine is approved for COVID-19?", asked Jolly. "Unfortunately a vaccine is never 100% effective," explained Dr. Chamberland. "There's always going to be a large percentage of people where the vaccine is not going to work. We're always going to see the acute respiratory response that is caused by the cytokine storm," he continued.

"The COVID crisis has given me, as a drug developer, an opportunity to decrease timelines in bringing a drug to the market. Not because I cut corners science-wise or regulatory-wise, but because the regulators are moving faster. That to me is a gift, I have to jump on it and I have to move it. Plus, we can make a difference in the fight against COVID."

Jolly then noted that the Company is grossly undervalued as a biotechnology company. "I agree with you. We are undervalued," said Dr. Chamberland, noting that the Company has been encouraged by a large volume of interest over the last month. "We stepped up and increased our IR activities to educate people on what we're doing - understanding our COVID-19 drug, but also understanding Reborn© and the potential in this market."

In closing, Dr. Chamberland also discussed the Company's Advanced Cancer Pain drug, QIXLEEF™, sharing that the funds needed to move this drug forward have been raised.

To hear Guy Chamberland's entire interview, follow the link to the podcast here: https://audioboom.com/posts/7613454-tetra-bio-pharma-discusses-the-potential-of-their-ards-003-drug-in-the-fight-against-covid-19-wit.

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/.

About Tetra Bio-Pharma

Tetra Bio-Pharma (TSXV: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed and approved, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, including the success of this product or any other product, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.:

Investor Contact:

Alpha Bronze, LLC
Mr. Pascal Nigen
Phone: + 1 (646) 255-0433
tetra@alphabronze.net

Media Contact:

energi PR
Ms. Carol Levine APR, FCPRS
Phone: + 1 (416) 425-9143 ext. 226
Mobile: + 1 (514) 703-0256
carol.levine@energipr.com

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.

SOURCE:

Stock Day Media
(602) 821-1102

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/58304

info